Newsfeeds Archive - Page 8 of 461

2 minute read

Sanofi Highlights Data From Blood Cancer Drug Sarclisa In New Diagnosed Multiple Myeloma Patients

June 4, 3:18 PM

Sanofi's phase 3 IMROZ study shows Sarclisa with VRd significantly improves progression-free survival in newly diagnosed, transplant-ineligible multiple myeloma patients.

SNY

2 minute read

Nano-Cap Equillium Shares Fall After Patchy Hair Loss Study Data

By Vandana Singh

June 4, 12:35 PM

Equillium released topline data from its Phase 2 study of EQ101 in adult patients with alopecia areata, a disease that results in patchy hair loss.

2 minute read

Mid-Cap Firm Annexon’s Nerve Disorder Candidate Shows Promise In Pivotal Late-Stage Study

By Vandana Singh

June 4, 12:06 PM

Annexon reports positive Phase 3 trial results for ANX005 in Guillain-Barré syndrome, showing significant improvements in disability, muscle strength, and ventilation duration.

ANNX

1 minute read

Bristol Myers Squibb Announces Phase 3 Results Of Opdivo/Yervoy Combo In Liver Cancer Patients

By Vandana Singh

June 4, 11:35 AM

Opdivo plus Yervoy combo shows significant survival benefits and higher response rates vs. lenvatinib/sorafenib in HCC.

BMY

2 minute read

What’s Going On With Viking Therapeutics Stock On Tuesday?

By Vandana Singh

June 4, 10:29 AM

Viking Therapeutics reports promising 52-week data from its Phase 2b VOYAGE study on VK2809 for NASH.

VKTX

2 minute read

US Department Penalizes 3 Airlines With $2.5M In Fines For Slow COVID-19 Refunds

By Vandana Singh

June 4, 10:06 AM

The U.S. Transportation Department has fined Lufthansa, KLM, and South African Airways $2.5 million for significant delays in issuing COVID-19-related refunds.

DLAKF

2 minute read

Nano-Cap Spruce Biosciences Collaborates With HMNC Brain Health To Develop Treatment for Major Depressive Disorder

By Vandana Singh

June 4, 7:02 AM

Spruce Biosciences collaborates with HMNC Brain Health to advance tildacerfont, a precision therapeutic for major depressive disorder, using the Cortibon Genetic Selection Tool.

SPRB

2 minute read

Structure Therapeutics’ Obesity Candidate Is ‘ Very Competitive’ To Eli Lilly’s Orforglipron, Analyst Says

By Vandana Singh

June 3, 3:14 PM

Structure Therapeutics reports positive 12-week Phase 2a obesity study results for GSBR-1290, showing a 6.2% weight loss. Cantor Fitzgerald maintains an Overweight rating with a $65 target

GPCR

2 minute read

GSK’s Blenrep Combo Therapy Cuts Risk Of Disease Progression Or Death By Around 50% In Pretreated Multiple Myeloma

By Vandana Singh

June 3, 3:08 PM

GSK presented interim results from the DREAMM-8 phase 3 trial at ASCO 2024. Blenrep (belantamab mafodotin) with PomDex showed a significant improvement in progression-free survival for relapsed or refractory multiple myeloma compared to bortezomib with PomDex.

GSK

2 minute read

Why Is German Biotech Affimed Stock Soaring On Monday?

By Vandana Singh

June 3, 2:13 PM

Affimed shares surged after positive updates from the AFM24-102 study in NSCLC. The study reported a 71% disease control rate and significant clinical activity, highlighting potential efficacy of AFM24 with atezolizumab.

AFMD